Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

Allogene Therapeutics, Inc.   NASDAQ (ALLO)

15.50    $-0.32   -2.02%
Market open   Monday, Oct 25 2021 13:21 PM

Allogene Therapeutics, Inc. Chart

ALLO Stock Price Today

Allogene Therapeutics, Inc. (ALLO) stock plummeted over -2.02% intraday to trade at $15.50 a share on NASDAQ. The stock opened with a loss of -0.38% at $15.76 and touched an intraday high of $15.87, rising 0.32% against the last close of $15.82. The stock went to a low of $15.30 during the session.

Stock Snapshot

15.82
Prev. Close
15.76
Open
2.27B
Market Cap
134.83M
Number of Shares
15.30
day Low
15.87
Day High
15.50
-
P/E ratio
10.77%
Free Float in %
-1.82
EPS (TTM)
7.59
Book Value per Share
4.10
Cash Flow per Share
430543
Volume

Allogene Therapeutics, Inc. Historical Data

DateOpenCloseDaily HighDaily LowVolume
2021-10-21$15.99$15.94$16.35$15.78963,800
2021-10-20$15.83$15.82$16.57$15.662,037,800
2021-10-19$15.89$15.74$16.27$15.481,425,200
2021-10-18$16.74$15.73$16.74$15.671,925,100
2021-10-15$17.21$16.48$17.35$16.402,778,500
2021-10-14$16.34$17.17$18.80$16.168,628,900
2021-10-13$13.40$15.94$16.88$13.3512,190,300
2021-10-12$13.46$13.43$13.68$13.015,817,800
2021-10-11$13.35$13.46$14.18$12.908,684,700
2021-10-08$15.97$13.13$16.01$13.1324,472,800
2021-10-07$24.07$24.38$25.00$23.882,124,000

Contact Details

210 East Grand Avenue
South San Francisco, CA 94080
United States
http://www.allogene.com
650 457 2700

About Company

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was founded in 2017 and is headquartered in South San Francisco, California.

Frequently Asked Questions

What is the current Allogene Therapeutics, Inc. (ALLO) stock price?

Allogene Therapeutics, Inc. (NASDAQ: ALLO) stock price is $15.50 as of the last check on Monday, Oct 25 2021. During the trading session, ALLO stock reached the peak price of $15.87 while $15.30 was the lowest point it dropped to.

ALLO's industry and sector of operation?

The NASDAQ listed ALLO is part of Biotechnology industry that operates in the broader Healthcare sector. Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.

Who are the executives of ALLO?

Dr. Arie S. Belldegrun F.A.C.S., M.D., FACS
Co-Founder & Exec. Chairman

Dr. David D. Chang M.D., Ph.D.
Co-Founder, Pres, CEO & Director

Mr. Joshua A. Kazam
Co-Founder & Director

Dr. Eric Thomas Schmidt Ph.D.
Chief Financial Officer


What is the ALLO stock price today?

ALLO stock is trading at $15.50 today, which is $-0.32 or -2.02% lower than its previous close of $15.82. ALLO's current trading price is -60.50% lower than its 52-week high of $39.12 where as its distance from 52-week low of $12.90 is 19.77%.

How many employees does ALLO have?

Number of ALLO employees currently stands at 265. ALLO operates from 210 East Grand Avenue South San Francisco, CA 94080 United States.

Link for ALLO official website?


How do I contact ALLO?

ALLO could be contacted at 210 East Grand Avenue South San Francisco, CA 94080 United States, or at phone # 650 457 2700 and can also be accessed through its website: http://www.allogene.com

How many shares of ALLO are traded daily?

ALLO stock volume so far today is 430543 shares while in the previous session number of ALLO shares traded was 963800. The average number of ALLO shares traded daily for last 3 months was 1.65M.

How much did ALLO change today?

The percentage change in ALLO stock occurred in the recent session was -2.02% while the dollar amount for the price change in ALLO stock was $-0.32.

What price range ALLO stock been trading in?

In the recent session, the day high for ALLO stock was $15.87 while the low for ALLO stock touched on the day was $15.30.

What is the market cap of ALLO currently?

The market value of ALLO currently stands at $2.27B with its latest stock price at $15.50 and 134.83M of its shares outstanding.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam